The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
Abstract
Aims: The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results: HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The primary endpoint was 6-minute walk test distance (6MWTD) change to Week 12. Key secondary endpoints included Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnoea score. 6MWTD median (95% confidence interval) differences, empagliflozin vs. placebo, at Week 12 were −4.0 m (−16.0, 6.0; P = 0.42) and 4.0 m (−5.0, 13.0; P = 0.37) in EMPERIAL-Reduced and EMPERIAL-Preserved, respectively. As the primary endpoint was non-significant, all secondary endpoints were considered exploratory. Changes in KCCQ-TSS and CHQ-SAS dyspnoea score were non-significant. Improvements with empagliflozin in exploratory pre-specified analyses of KCCQ-TSS responder rates, congestion score, and diuretic use in EMPERIAL-Reduced are hypothesis generating. Empagliflozin adverse events were consistent with those previously reported. Conclusion: The primary outcome for both trials was neutral. Empagliflozin was well tolerated in HF patients, with and without T2D, with a safety profile consistent with that previously reported in T2D. Hypothesis-generating improvements in exploratory analyses of secondary endpoints with empagliflozin in HFrEF were observed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and SGLT2 inhibition did not improve 6MWD in patients with HFpEF in 2 trials.29,30”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [30]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citation2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citation
Cited by
Heart Failure With Preserved Ejection Fraction: A Review
Redfield, M. M., & Borlaug, B. A. (2023) · JAMA · doi:10.1001/jama.2023.2020 · Cited by 662
Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01536-x · Cited by 618
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
“In HF, empagliflozin administration was associated with improved clinical outcomes for the HFrEF phenotype [62], and the overall risk of HF events between HFrEF and HFpEF was reduced by canagliflozin [63], dapagliflozin [64], and ertugliflozin [65].”
BackgroundBorlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
Lindenfeld, J., Zile, M. R., Desai, A. S., Bhatt, K., Ducharme, A., Horstmanshof, D., Krim, S. R., Maisel, A., Mehra, M. R., Paul, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01754-2 · Cited by 432
Self-citation
Metadata
- Authors
- Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., Howlett, J. G., Nicholls, S. J., Redon, J., Schenkenberger, I., Silva-Cardoso, J., Störk, S., Krzysztof Wranicz, J., Savarese, G., Brueckmann, M., Jamal, W., Nordaby, M., Peil, B., Ritter, I., Ustyugova, A., Zeller, C., Salsali, A., & Anker, S. D.
- Affiliations
- The Ohio State University (US)
- Vanderbilt University Medical Center (US)
- Wroclaw Medical University (PL)
- University of Milan (IT)
- University of Mississippi Medical Center (US)
- Brigham and Women's Hospital (US)
- National and Kapodistrian University of Athens (GR)
- Department of Cardiology, Independent Public Healthcare , General Hospital in Puławy; ul. Bema 1; 24 – 100 Pulawy, Poland
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Calgary (CA)
- Monash University (AU)
- INCLIVA Research Institute, University of Valencia , vinguda de Menéndez y Pelayo, 4, 46010 Valencia, and CIBERObn, Madrid, Spain
- Klinische Forschung Berlin GbR , Ansbacher Str. 17-19, 10787 Berlin, Germany
- CardioCare, CINTESIS—Center for Health Technology and Services Research, and Director of the Cardiology Service, Porto University Medical School , São João University Medical Centre, Rua Dr. Plácido da Costa, s/n 4200-450, Porto, Portugal
- University of Würzburg (DE)
- Department of Electrocardiology, Medical University of Lodz , al. Tadeusza Kościuszki 4, 90-41, Lodz, Poland
- Karolinska University Hospital (SE)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (United States) (US)
- Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
- Corresponding author
- Abraham, William T
- ORCID
- Abraham, William T
- Lindenfeld, JoAnn
- Ponikowski, Piotr
- Agostoni, Piergiuseppe
- Butler, Javed
- Desai, Akshay S
- Filippatos, Gerasimos
- Gniot, Jacek
- Fu, Michael
- Gullestad, Lars
- Howlett, Jonathan G
- Nicholls, Stephen J
- Störk, Stefan
- Savarese, Gianluigi
- Brueckmann, Martina
- Jamal, Waheed
- Nordaby, Matias
- Ritter, Ivana
- Zeller, Cordula
- Salsali, Afshin
- Anker, Stefan D
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-22
- Volume
- 42
- Issue
- 6
- Pages
- 700-710
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W3115628228
- Cited by
- 217
- References
- 28
- Citations by year
- 2026: 21 · 2025: 36 · 2024: 43 · 2023: 47 · 2022: 39 · 2021: 29 · 2020: 2
- FWCI
- 18.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Keywords
- empagliflozin, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, type 2 diabetes, SGLT2 inhibitors, exercise capacity, 6-minute walk test, patient-reported outcomes, Kansas City Cardiomyopathy Questionnaire, dyspnea, diuretic use, drug safety and tolerability
- MeSH terms
- Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa943
- The paper
- Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., Howlett, J. G., Nicholls, S. J., Redon, J., Schenkenberger, I., Silva-Cardoso, J., Störk, S., Krzysztof Wranicz, J., Savarese, G., Brueckmann, M., . . . Anker, S. D. (2021). Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.